Dr. Reddy's and Pharmazz inks agreement to market Centhaquine for hypovolemic shock in India
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Dr Madhu will oversee Apollo's hospital business and will focus on continuing to deliver the world's best clinical outcomes
To accelerate the development of next-generation radioconjugates to treat cancer
Additional capacity broadens Grace’s fine chemical capabilities for API production
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Subscribe To Our Newsletter & Stay Updated